John H. Ward, MD, professor of Medicine, Huntsman Cancer Institute, University of Utah, discusses his preferences in multilane testing for patients with hormone receptor-positive, node-negative breast cancer.

For a patient who would be considered for chemotherapy, Ward recommends the 21-gene panel as it is believed to be predictive of chemotherapy benefit. However, if a patient has already had other assays, it is unnecessary to repeat testing with the 21-gene panel.

Ward says there is no wrong choice when it comes to selecting the panel, but the 21-gene is his preference. For patients in which chemotherapy is not being considered, the panel is also not needed as it will not affect the treatment decision.

свернуть